Format

Send to

Choose Destination
Trends Pharmacol Sci. 2008 Jul;29(7):361-6. doi: 10.1016/j.tips.2008.04.001. Epub 2008 May 22.

Mitochondrial off targets of drug therapy.

Author information

1
Department of Biochemistry and Molecular Biology, University of Minnesota Medical School, Duluth, MN 55812, USA. kwallace@d.umn.edu

Abstract

The bioenergetic features of mitochondria have long been exploited in the design of pharmacological agents suited to accomplish a desired physiological effect; uncoupling of oxidative phosphorylation to induce weight loss, for example. However, more recent experience demonstrates mitochondria to be unintended off targets of other drug therapies and responsible, at least in part, for the dose-limiting adverse events associated with a large array of pharmaceuticals. Review of the fundamentals of mitochondrial molecular biology and bioenergetics reveals a multiplicity of off targets that can be invoked to explain drug-induced mitochondrial failure. It is this redundancy of mitochondrial off targets that complicates identification of discrete mechanisms of toxicity and confounds QSAR-based design of new small molecules devoid of this potential for mitochondrial toxicity. The present review article briefly reviews the molecular biology and biophysics of mitochondrial bioenergetics, which then serves as a platform for identifying the various potential off targets for drug-induced mitochondrial toxicity.

PMID:
18501972
DOI:
10.1016/j.tips.2008.04.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center